Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Clinical Trials

A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.

Phase 1

Conditions: Ovarian Cancer

Interventions: Drug: Sevacizumab
Drug: Paclitaxel
Drug: Topotecan

First Posted Date: 2018-12-04

Last Posted Date: 2018-12-04

Lead Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT03763123

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Wuhan Union Hospital, Wuhan, Hunan, China
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 3 locations

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase 1

Active, not recruiting

Conditions: Rhabdoid Tumor
Solid Tumors
Medulloblastoma
Ewing Sarcoma
Rhabdomyosarcoma
Diffuse Intrinsic Pontine Glioma
Neuroblastoma

Interventions: Drug: Palbociclib
Drug: Temozolomide
Drug: Cyclophosphamide
Drug: Irinotecan
Drug: Topotecan

First Posted Date: 2018-10-17

Last Posted Date: 2025-01-14

Lead Sponsor: Pfizer

Target Recruit Count: 128

Registration Number: NCT03709680

Locations: 🇸🇰
Detska fakultna nemocnica s poliklinikou Banska Bystrica, Banska Bystrica, Slovakia
🇺🇸
University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States

and more 95 locations

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Phase 1

Active, not recruiting

Conditions: Ewing Sarcoma
Clear Cell Sarcoma
Myoepithelial Tumor
Desmoplastic Small Round Cell Tumor
Angiomatoid Fibrous Histiocytoma
Myxoid Liposarcoma
Sarcoma,Soft Tissue
Extraskeletal Myxoid Chondrosarcoma
Sclerosing Epithelioid Fibrosarcoma
Fibromyxoid Tumor

Interventions: Drug: Seclidemstat
Drug: Cyclophosphamide
Drug: Topotecan

First Posted Date: 2018-07-26

Last Posted Date: 2023-11-21

Lead Sponsor: Salarius Pharmaceuticals, LLC

Target Recruit Count: 50

Registration Number: NCT03600649

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States

and more 12 locations

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Phase 1

Completed

Conditions: Carcinoma, Small Cell
Lung Cancer
Small Cell Lung Cancer

Interventions: Drug: M7824
Drug: Topotecan
Drug: Temozolomide
Diagnostic Test: EKG
Diagnostic Test: CT scan
Diagnostic Test: PET scan
Drug: Acetaminophen
Drug: Antihistamines
Drug: Diphenhydramine
Drug: Dexamethasone
Drug: Epinephrine

First Posted Date: 2018-06-13

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 37

Registration Number: NCT03554473

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Weekly paclitaxel
Drug: Topotecan
Drug: Bevacizumab

First Posted Date: 2017-12-08

Last Posted Date: 2019-01-11

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT03367182

Locations: 🇰🇷
Severance hospital, Seoul, Korea, Republic of

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

Phase 2

Active, not recruiting

Conditions: Essential Thrombocythemia
Atypical Chronic Myeloid Leukemia
Myelodysplastic/Myeloproliferative Neoplasm
Myelofibrosis
Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Polycythemia Vera
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Drug: Carboplatin
Drug: Topotecan
Drug: Topotecan Hydrochloride
Drug: Veliparib

First Posted Date: 2017-09-21

Last Posted Date: 2025-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT03289910

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

and more 3 locations

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Phase 1

Conditions: Small Cell Lung Cancer SCLC

Interventions: Drug: veliparib
Drug: Topotecan

First Posted Date: 2017-07-24

Last Posted Date: 2021-01-27

Lead Sponsor: Central European Society for Anticancer Drug Research

Target Recruit Count: 30

Registration Number: NCT03227016

Locations: 🇩🇪
Klinik München Gauting, München Gauting, Germany

Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy

Early Phase 1

Withdrawn

Conditions: Glioma

Interventions: Drug: Topotecan (>8cc)
Drug: Topotecan (<=8cc)
Device: Cleveland Multiport Catheter
Drug: Lower Does Topotecan
Diagnostic Test: Magnetic Resonance Imaging (MRI)

First Posted Date: 2017-06-20

Last Posted Date: 2019-03-01

Lead Sponsor: Michael Vogelbaum, MD, PhD

Registration Number: NCT03193463

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

Phase 2

Terminated

Conditions: Very High Risk Neuroblastoma

Interventions: Radiation: mIBG
Drug: Thiotepa
Drug: Topotecan
Procedure: Autologous stem cell transplant

First Posted Date: 2017-05-24

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 34

Registration Number: NCT03165292

Locations: 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇦🇹
St. Anna Kinderspital GmbH, Vienna, Austria
🇮🇹
Fondazione IRCCS Istituto nazionaleTumori, Milano, Italy

and more 6 locations

Chronic Convection Enhanced Delivery of Topotecan

Phase 1

Completed

Conditions: Gliomas

Interventions: Drug: Topotecan
Drug: Gadolinium
Device: Synchromed II infusion pumps

First Posted Date: 2017-05-16

Last Posted Date: 2022-07-05

Lead Sponsor: Jeffrey N. Bruce

Target Recruit Count: 5

Registration Number: NCT03154996

Locations: 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy